The Vanguard Group 13D and 13G filings for Deciphera Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:02 pm Sale | 2023-12-29 | 13G | Deciphera Pharmaceuticals, Inc. DCPH | The Vanguard Group | 4,401,636 5.490% | -343,685 (-7.24%) | Filing |
| 2023-02-09 11:16 am Purchase | 2022-12-30 | 13G | Deciphera Pharmaceuticals, Inc. DCPH | The Vanguard Group | 4,745,321 7.020% | 1,276,004 (+36.78%) | Filing |
| 2022-02-09 3:43 pm Sale | 2021-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH | The Vanguard Group | 3,469,317 5.930% | -366,441 (-9.55%) | Filing |
| 2021-02-10 10:46 am Purchase | 2020-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH | The Vanguard Group | 3,835,758 6.740% | 3,835,758 (New Position) | Filing |